China bladder cancer market was valued at $486.4 million in 2025 and is projected to reach $921.0 million by 2035, growing at a CAGR of 6.7% during the forecast period (2026–2035). The bladder cancer market in China is gradually expanding as more advanced diagnostic tools, such as biomarker and molecular panels, are being adopted. These emerging technologies are transforming bladder cancer diagnostics, offering more precise and personalized approaches for early detection, especially for high-risk and recurrent cases. The development and use of urinary urothelial cancer early detection kits are particularly gaining attention, as they provide a non-invasive, highly specific method to identify bladder cancer at earlier stages, potentially improving patient outcomes. For instance, in March 2024, Shanghai Yipu Biotechnology Co., Ltd. announced the development of a multi-marker urine qPCR kit for the detection of urothelial cancers, which received Breakthrough Device recognition from the U.S. FDA. This marks the first urine-based product capable of simultaneously detecting bladder cancer, ureteral cancer, and renal pelvis cancer using independently developed cancer markers. The Breakthrough Designation suggests strong international potential and paves the way for future commercialization in multiple markets. The growing need for early and accurate detection in a country with a large and aging population is driving the demand for these innovative diagnostic solutions. As precision medicine becomes more integrated into clinical practice, biomarker panels are helping to assess prognosis, predict treatment responses, and monitor disease recurrence. These advancements are expected to play a critical role in shaping the future of bladder cancer care in China, ultimately supporting market expansion and improving patient management. Through continuous technological progress, the market for these diagnostic tools is poised for steady growth.
Browse the full report description of “China Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other), 2026–2035)” at https://www.omrglobal.com/industry-reports/china-bladder-cancer-market
Leading Companies and Diagnostic Advances
The major companies operating in the China bladder cancer market include BeiGene, Ltd., Eli Lilly and Company, Pfizer Inc., Bristol?Myers Squibb Company, Astellas Pharma Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Market Coverage
Key questions addressed by the report.
China Bladder Cancer Market Report Segment
Cancer Type
Diagnosis Method
By Therapy
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-bladder-cancer-market